Risk Management Strategies in the Postmarketing Period: Safety Experience with the US and European Bosentan Surveillance Programmes

Author： Segal Eleanor S.   Valette Cecile   Oster Laurence   Bouley Luc   Edfjall Catarina   Herrmann Peter   Raineri Massimo   Kempff Mary   Beacham Saundra   Cinda van Lierop  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.28, Iss.11, 2005-01, pp. : 971-980

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Postmarketing Safety Surveillance: Issues with Data Collection for Postmarketing Pharmacovigilance

By Prabhakar Upasana   Edwards Brian  

Pharmaceutical Medicine, Vol. 24, Iss. 6, 2010-12 ,pp. : 343-348

Adis International

Access to resources Recommend Favorite

Postmarketing Drug Safety Surveillance: An Overview of Regulatory Issues

By Wu J.H.  

Pharmaceutical Development and Regulation, Vol. 1, Iss. 4, 2003-01 ,pp. : 231-244

Adis International

Access to resources Recommend Favorite

US FDA addresses postmarketing drug surveillance concerns

By  

Reactions Weekly, Vol. 1, Iss. 1030, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

US FDA addresses postmarketing drug surveillance concerns

By  

Inpharma, Vol. 1, Iss. 1466, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Safety of Zafirlukast: Results of a Postmarketing Surveillance Study on 7976 Patients in England

By Twaites Beverley R.   Wilton Lynda V.   Shakir Saad A.W.  

Drug Safety, Vol. 30, Iss. 5, 2007-01 ,pp. : 419-429

Adis International

Access to resources Recommend Favorite